Argenx Se (ARGX) Net Income towards Common Stockholders (2016 - 2026)
Argenx Se (ARGX) posted Net Income towards Common Stockholders of $366.0 million for Q1 2026, down 31.33% on a QoQ basis from $532.9 million in Q4 2025, and up 116.57% year-over-year from $169.0 million in Q1 2025.
Argenx Se (ARGX) Net Income towards Common Stockholders (2016 - 2026) Analysis & Trends
Argenx Se's Net Income towards Common Stockholders history runs 11 years deep, the most recent figure standing at $366.0 million for Q1 2026.
- Quarterly Net Income towards Common Stockholders rose 116.57% year-over-year to $366.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.5 billion (up 39.95% YoY) and the FY2025 annual result came in at $1.3 billion, up 55.1% from the prior year.
- Net Income towards Common Stockholders was $366.0 million for Q1 2026 at Argenx Se, down from $532.9 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at $774.2 million in Q4 2024 and bottomed at -$235.0 million in Q3 2022.
- A 5-year average of $138.7 million and a median of $29.1 million in 2024 frame the typical range for Net Income towards Common Stockholders.
- Annual changes were most pronounced in 2022 — Net Income towards Common Stockholders tumbled 461.88% — and 2024, when it soared 880.62%.
- Argenx Se's Net Income towards Common Stockholders stood at -$38.6 million in 2022, then slumped by 156.84% to -$99.2 million in 2023, then surged by 880.62% to $774.2 million in 2024, then tumbled by 31.16% to $532.9 million in 2025, then slumped by 31.33% to $366.0 million in 2026.
- Business Quant data shows ARGX's Net Income towards Common Stockholders at $366.0 million in Q1 2026, $532.9 million in Q4 2025, and $344.3 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -625.73 |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -0.68 |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 366.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | Alnylam Pharmaceuticals | 36.08 Bn | 33.07 Bn | 959.66 Mn | 205.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 366.00 Mn |
| Dec 31, 2025 | 532.95 Mn |
| Sep 30, 2025 | 344.26 Mn |
| Jun 30, 2025 | 245.36 Mn |
| Mar 31, 2025 | 169.00 Mn |
| Dec 31, 2024 | 774.16 Mn |
| Sep 30, 2024 | 91.41 Mn |
| Jun 30, 2024 | 29.07 Mn |
| Mar 31, 2024 | -61.60 Mn |
| Dec 31, 2023 | -99.17 Mn |
| Sep 30, 2023 | -72.64 Mn |
| Jun 30, 2023 | -94.37 Mn |
| Mar 31, 2023 | -28.87 Mn |
| Dec 31, 2022 | -38.61 Mn |
| Sep 30, 2022 | -235.04 Mn |
| Jun 30, 2022 | 663.12 Mn |
| Mar 31, 2022 | -227.19 Mn |
| Dec 31, 2021 | -237.82 Mn |
| Sep 30, 2021 | -233.61 Mn |
| Jun 30, 2021 | 103.60 Mn |